attempt to investigate the potential susceptibility of MSCs to undergoing malignant transformation. TA was determined using the telomeric repeat amplification protocol, a PCR-based method in which telomerase extends a radiolabeled synthetic primer resembling telomeric DNA, 8 in isolated cells. ALT was detected by assaying ALT-associated promyelocytic leukemia (PML) nuclear bodies, using a combined technique of PML immunofluorescence and telomere FISH, 8 in fresh cultures obtained from MM and MGUS patients. Notably, no alteration was found in all tested MSCs and OBs regarding either TA (Figure 1b) or ALT (data not shown), suggesting that both cell types do not have an immortalized phenotype.
MPN. Given that the IDH-mutated cases were not associated with any specific recurrent cytogenetic abnormality and given that only three of the nine cases harbored JAK2V617F concurrently further suggested that IDH mutations have a pathogenetic role in leukemic transformation of MPN.
In light of the aforementioned observations, we were curious as to whether this followed a general principle; that is whether acquisition of IDH mutation is associated with disease transformation or progression in myeloid malignancies other than MPN. For a disease model in this regard, we chose to focus on myelodysplastic syndrome (MDS) associated with isolated deletion of chromosome 5q. We recently reported on 88 consecutive Mayo Clinic patients who fit the 2008 World Health Organization (WHO) definition for 'MDS with isolated del(5q)'. 3 The current WHO definition for this low-risk MDS entity requires the presence of an isolated del(5q), a blast count of o5% in the bone marrow (BM) and o1% in the peripheral blood, and absence of Auer rods. 4 This entity shares clinical and pathological features, but is not synonymous with the traditionally defined '5q minus syndrome,' which is characterized by macrocytic anemia, erythroid hypoplasia, normal or elevated platelet count, hypolobulated megakaryocytes and isolated del(5q). In this particular study, five (6%) and three (4%) patients were found to harbor the JAK2V617F and MPLW515L mutations, respectively, but none carried IDH mutations. However, it should be noted that among the broader population of MDS patients with isolated del(5q), many do not meet the WHO criteria for 'MDS with isolated del(5q)'; these include high-risk MDS cases with excess peripheral blood or BM blasts (for example, RAEB-1 and RAEB-2), or with therapy-related MDS (t-MDS), or those who only satisfy the criteria for MDS unclassifiable (MDS-U). Furthermore, isolated del(5q) abnormality can also occur in other myeloid malignancies including AML. Therefore, our aim was to use the relatively well-defined patient population characterized by presence of del(5q) as the sole cytogenetic abnormality to assess whether IDH mutation acquisition was associated with progressive or transformed disease (that is, high-risk MDS or AML) as compared with patients with lowerrisk disease (that is, 'MDS with isolated del(5q)').
After approval by the Mayo Clinic Institutional Review Board, we queried an institutional cytogenetic database from 1989 to 2009, in order to identify patients whose BM karyotype analysis revealed at least two metaphases with isolated deletions of chromosome 5q. Medical records, BM and cytogenetic specimens were reviewed in all cases to ensure accuracy of each diagnosis, which was assigned as per the 2008 WHO classification system. Those patients who met the 2008 WHO criteria for 'MDS with isolated del(5q)' have been previously reported. Archived BM cell pellets were stored at À70 1C in methanol:glacial acetic acid (2:1) fixative. After appropriate washing techniques, the DNA on these patients was extracted using the Qiagen DNA Mini extraction kit (Qiagen, Santa Clarita, CA, USA) and analyzed for JAK2V617F and MPL (exon 10) mutations, using the previously described methods.
Samples were analyzed for IDH1 exon 4 mutations using the following primer sequences: sense, 5
0 -CGGTCTTCAGAGAAG CCATT-3 0 ; and antisense, 5 0 -CACATTATTGCCAACATGAC-3 0 .
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IDH2 exon 4 was amplified using sense, 5 0 -CCACTATTATCTC TGTCCTC-3 0 ; and antisense, 5 0 -GCTAGGCGAGGAGCTCC AGT-3 0 . 6 Briefly, both reactions were carried out in 25-ml volume containing 100 ng of DNA, 0.25 U Taq polymerase, 0.3 mM each of dATP, dCTP, dGTP and dTTP, 5 ml of a 10 Â PCR buffer (Roche Diagnostics, Indianapolis, IN, USA), and 0.2 mM each of sense and antisense primers. The reaction was denatured at 94 1C for 3 min followed by 35 cycles of denaturing at 94 1C for 30 s, annealing at 57 1C for 30 s and extension at 72 1C for 40 s. After a final extension at 72 1C for 2 min, the products were confirmed by 1.3% agarose gel and purified using Qiagen's PCR Quick Purification Kit. The product was sequenced using the ABI PRISM 3730xl analyzer (Applied Biosystems, Foster City, CA, USA) to screen for the presence of mutations.
In addition to direct sequencing, samples were also analyzed by high-resolution melting (HRM) assay using the LightCycler 480 real-time PCR system (Roche Diagnostics
Screening for JAK2V617F and JAK2 46/1 haplotype analysis was carried out as previously described. 7 We identified 86 cases of hematological malignancy associated with isolated del(5q), in addition to the previously reported 78 cases of WHO-defined 'MDS with isolated del(5q)'. 3 Of the former group, we identified 27 cases with either high-risk MDS or AML; of these, 16 patients had high-risk MDS (RAEB-2 ¼ 9; RAEB-1 ¼ 6; post-AML MDS ¼ 1) and 11 had AML (de novo AML ¼ 7; secondary AML ¼ 4, of which 3 had post-MDS AML and 1 post-polycythemia vera AML). In contrast to 'MDS with isolated del(5q)' in which we previously failed to identify IDH mutations, 6 of the 27 patients with high-risk MDS or AML with isolated del(5q) harbored an IDH mutation (prevalence ¼ 22%) (Table 1) ; the prevalence in both high-risk MDS (4 of 16 cases) and secondary AML (1 of 4 cases) was 25%. Five of the six IDH-mutated cases harbored the IDH2 R140Q allele; the sole IDH1-mutated case harbored the R132G mutation. The IDH mutations were heterozygous in every instance, and similar to a previous report, 1 we found no cases of IDH2 R172 mutation in the present cohort. Only one patient with AML, who predictably had antecedent polycythemia vera, harbored JAK2V617F and IDH2 R140Q mutations concurrently ( Table 1) . Also of interest to us was the observation that all IDH mutation-positive highrisk MDS patients with isolated del(5q) were nullizygous for the JAK2 46/1 haplotype; the significance of this finding remains unclear given the relatively small number of cases in the present cohort.
Thus, in the relatively well-defined patient population characterized by presence of del(5q) as the sole cytogenetic abnormality, IDH mutation frequency was significantly greater in high-risk MDS or AML as compared with those with low-risk 'MDS with isolated del(5q)' (22 versus 0%; Po0.01). This observation is remarkably similar to MPN, in which IDH mutations are overrepresented in leukemic phase as compared with chronic phase of the disease. 1 An advantage in the case of the former analysis is that the presence of del(5q) as the sole abnormality in both low-and high-risk groups eliminates a major confounder in the assessment of genetic events potentially associated with disease transformation or progression. Overall, this supports the view that acquisition of IDH mutations has a pathogenetic role in disease evolution, although the precise mechanism for this effect remains unclear. On the basis of the current analysis, IDH mutations do not seem to induce genomic instability, at least as evidenced by acquisition of new cytogenetic changes, as the basis for disease evolution. We believe it will be of interest to see whether the same general principle of selective association of IDH mutations with transformed or progressive disease is obeyed in other conditions; in this regard, we believe that similar studies in myelofibrotic transformation of MPN, blast phase of chronic myeloid leukemia and MDS patients without isolated del(5q) will be of value.
Acute monoblastic leukemia, also designated as AML5 subtype, is characterized by accumulation of monoblastic-like cells (AML5 blasts), which terminal differentiation is blocked. The AML5 subtype poorly responds to chemotherapy and still has bad prognosis. We have previously reported that CD44-ligation with specific monoclonal antibodies (mAbs) can reverse differentiation blockage in AML5 subtype, 1 providing strong basis for the development, in AML5, of a CD44-targeted differentiation therapy that could be as efficient as that with retinoic acid in the promyelocytic AML subtype.
By monitoring differentiation using the gradual increase in expression of CD11b and CD14 monocytic-lineage antigens, we have recently shown that CD44-ligation triggers in AML5 blasts, a burst of cytokine synthesis, and that granulocytemacrophage colony-stimulating factor(GM-CSF) and interleukin (IL)-8 are required to increase the expression of CD14.
2 However, the mechanisms involved in CD44-induced differentiation, and especially in differentiating cytokine synthesis, are still unknown. Here, using the THP-1 monoblastic cell line as a model of AML5 blasts, and Hermes-3 anti-CD44 mAb (H3) to induce its differentiation, we show that CD44-ligation induces, through extracellular signal-regulated kinases (ERK)1/2 pathway, the synthesis of cytokines tumor necrosis factor (TNF)-a and IL-6 required for monocytic differentiation of these leukemic cells. Abbreviations: AML, acute myeloid leukemia; F, female; f/u, follow-up; G, glycine; IDH, isocitrate dehydrogenase; JAK2, Janus kinase 2; M, male; MDS, myelodysplastic syndrome; neg., negative; pos., positive; PV, polycythemia vera; Q, glutamine; R, arginine; RAEB, refractory anemia with excess blasts; WHO, World Health Organization.
